Radioembolization for hepatocellular carcinoma.

Area of Science:

• Hepatobiliary Medicine
• Interventional Radiology
• Nuclear Medicine

Background:

• Radioembolization (RE) is a brachytherapy utilizing intra-arterial Yttrium-90 (90Y) microspheres for internal radiation.
• It demonstrates high disease control rates (>80%) and is generally well-tolerated, with complications typically arising from non-target tissue irradiation rather than microembolism.

Purpose of the Study:

• To evaluate the efficacy and role of radioembolization in managing hepatocellular carcinoma (HCC).
• To compare radioembolization with standard treatments like transarterial embolization (TACE) and sorafenib for intermediate and advanced HCC stages.

Main Methods:

• Review of retrospective and prospective studies, including large series totaling nearly 700 patients.
• Comparative analysis of radioembolization outcomes against established therapies for HCC.

Main Results:

• Radioembolization achieves disease control rates exceeding 80% and offers survival rates comparable to transarterial embolization and sorafenib.
• It presents promising indications for first-line treatment in specific patient groups, including those with bulky or advanced disease, and for downstaging prior to radical treatment.

Conclusions:

• Radioembolization is a valuable therapeutic option for hepatocellular carcinoma, particularly in intermediate and advanced stages.
• It shows significant potential as a first-line treatment and for downstaging, adding value to the management of HCC in specialized centers.